NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Zenas BioPharma, Inc. (ZBIO) Stock Analysis

Zenas BioPharma, Inc. (ZBIO) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ZBIO

$32.88

−$0.04 (−0.12%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ZBIO with… →

ZBIO Key Statistics

As of Sep 4, 2026
Trading
Open
$32.66
Previous Close
$32.92
Day's Range
32.38–33.29
52-Week Range
13.50–44.60
Volume
452.70K
Valuation
Market Cap
$2.14B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2143.01
EPS (ttm)Profit attributable to each share over the last twelve months.
−9.62
Financials (FY)
Revenue (FY)
$10.00M+100.00%
Net Income (FY)
−$377.74M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
65.18M
1-Year Return
+93.64%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
847.16K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ZBIO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−9.45%
2025+343.35%
2024 (partial year)−54.88%

As of September 4, 2026.

ZBIO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$10.00M−$377.74M−3777.4%
2024$5.00M−$156.99M−3139.8%
2023$50.00M−$37.12M−74.2%
2022$0.00−$119.28M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$10.00M—−$211.39M−$377.74M−3777.4%
2024$5.00M—−$163.89M−$156.99M−3139.8%
2023$50.00M—−$27.15M−$37.12M−74.2%
2022$0.00—−$75.20M−$119.28M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ZBIO Valuation vs Biotechnology Median

Median of 656 stocks
MetricZBIOBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Zenas BioPharma, Inc. (ZBIO) is capitalised at $2.14B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 167.

The 52-week range on file runs from $13.50 to $44.60. ZBIO last closed at $32.88 on September 4, 2026. That is −$0.04 (−0.12%) against the previous close. The latest close sits 143.56% above that 52-week low.

Financial Health

In fiscal 2025, Zenas BioPharma, Inc. reported revenue of $10.00M. That is +100.00% against the prior fiscal year, when revenue was $5.00M. The same year closed with a net loss of $377.74M. The reported profit margin is 0%. Earnings per share on a trailing basis come to −9.62.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $10.00M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 2,143.01 times revenue. On price-to-sales that is 140.4 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the price has returned +93.64%. The stored price history starts on September 13, 2024, and the total return since then is +81.16%. Daily returns over the trailing 2 years annualize to a volatility of 104.35%.

Growth & Income

The record shows no dividend for ZBIO.

The record holds one complete calendar year, 2025, which returned +343.35%. 2026 is still running; the price is −9.45% year to date.

Peer Comparison

Zenas BioPharma, Inc. (ZBIO) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Zenas BioPharma, Inc. ZBIO $2.14B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Zenas BioPharma, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Zenas BioPharma, Inc.

Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an extended half-life versus; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Visit website →